Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice.
|
25320360 |
2014 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity.
|
24429876 |
2014 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation.
|
23937717 |
2013 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant.
|
23664448 |
2013 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 50% of lung cancer patients with epidermal growth factor receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) reportedly carry a secondary EGFR T790M mutation.
|
22899358 |
2012 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic analysis suggested that the specific EGFR mutation L858R in exon 21 might be the main factor contributing to lung carcinogenesis in multiple lung cancers.
|
22733594 |
2012 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The loop-hybrid mobility shift assay (LH-MSA) was previously developed for the rapid detection of the EGFR mutation L858R for predicting clinical responses to gefitinib in lung cancer.
|
21741959 |
2011 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
|
20574956 |
2010 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aim to develop a digital PCR-based method for the quantitative detection of the two common epidermal growth factor receptor (EGFR) mutations (in-frame deletion at exon 19 and L858R at exon 21) in the plasma and tumor tissues of patients suffering from non-small cell lung cancers.
|
19276259 |
2009 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The EGFR mutation status, especially L858R mutation might be correlated with the clinico-pathological features related to good response to gefitinib, such as gender, smoking history, and pathological subtypes of Japanese lung cancers.
|
16890322 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using the LightCycler PCR assay, the EGFR L858R mutation status might correlate with gender, pathologic subtypes, and gefitinib sensitivity of lung cancers.
|
15837743 |
2005 |